Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Short-term Investments (2019 - 2025)

Sunshine Biopharma filings provide 5 years of Short-term Investments readings, the most recent being $70457.0 for Q1 2025.

  • On a quarterly basis, Short-term Investments changed N/A to $70457.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $70457.0, a N/A change, with the full-year FY2021 number at $7590.0, changed 0.0% from a year prior.
  • Short-term Investments hit $70457.0 in Q1 2025 for Sunshine Biopharma, up from $7590.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $70457.0 in Q1 2025 to a low of $7590.0 in Q1 2021.
  • Median Short-term Investments over the past 3 years was $7590.0 (2021), compared with a mean of $15448.4.
  • The widest YoY moves for Short-term Investments: up 0.0% in 2021, down 0.0% in 2021.
  • Sunshine Biopharma's Short-term Investments stood at $7590.0 in 2021, then changed by 0.0% to $7590.0 in 2022, then soared by 828.29% to $70457.0 in 2025.
  • The last three reported values for Short-term Investments were $70457.0 (Q1 2025), $7590.0 (Q3 2022), and $7590.0 (Q2 2022) per Business Quant data.